The primary barrier to he clinical development of α-LGR5 in the three therapeutic modalities are safety studies with a suitable animal model in order to evaluate the potential for on-target/off-tumour effects on stem cell compartments that express LGR5. Here, LGR5 is linked to neoplasm.